Content about Pfizer

January 2, 2013

The Food and Drug Administration last week approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots in patients with atrial fibrillation that is not caused by a heart valve problem. Eliquis is manufactured by Bristol-Myers Squibb, and marketed by BMS and Pfizer.

PRINCETON, N.J. — The Food and Drug Administration last week approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots in patients with atrial fibrillation that is not caused by a heart valve problem. Eliquis is manufactured by Bristol-Myers Squibb, and marketed by BMS and Pfizer.

December 28, 2012

Mylan on Friday announced that its subsidiary, Mylan Pharmaceuticals, has received final approval from the U.S. Food and Drug Administration for its phenytoin chewable tablets USP in the 50 mg strength.

 PITTSBURGH — Mylan on Friday announced that its subsidiary, Mylan Pharmaceuticals, has received final approval from the U.S. Food and Drug Administration for its phenytoin chewable tablets USP in the 50 mg strength.

The product is a generic version of Pfizer's Dilantin Chewable Tablets, which are indicated for the control of generalized tonic-clonic (i.e., grand mal) and complex partial (i.e., psychomotor, temporal lobe) seizures, and prevention and treatment of seizures occurring during or following neurosurgery.

December 27, 2012

Demand for SeroVital-hgh — a proprietary amino acid compound developed by Sierra Research Labs — has spiked in the past month. To help meet demand, the company on Dec. 21 announced distribution expansion through GNC.

NEW YORK — Demand for SeroVital-hgh — a proprietary amino acid compound developed by Sierra Research Labs — has spiked in the past month, in part due to recent exposure on news channels like CNN and on news programs like "The Today Show," the company announced last week. To help meet demand, the company on Dec. 21 announced distribution expansion through GNC. 

December 12, 2012

Pfizer Consumer Healthcare on Wednesday introduced Robitussin CoughCast, a new interactive tool that allows people to track cough activity in their local area.

MADISON, N.J. — Pfizer Consumer Healthcare on Wednesday introduced Robitussin CoughCast, a new interactive tool that allows people to track cough activity in their local area. 

According to the company, already this year nearly 18.2 million U.S. adults have experienced cold and flu symptoms, and more than 18 million have reported suffering from cough, making it one of the most highly reported symptoms.

December 11, 2012

Biotech and vaccines company Nuron Biotech has bought rights from Pfizer for a vaccine to prevent infection by a bacteria that is a major cause of infectious disease around the world.

EXTON, Pa. — Biotech and vaccines company Nuron Biotech has bought rights from Pfizer for a vaccine to prevent infection by a bacteria that is a major cause of infectious disease around the world.

December 3, 2012

Pfizer on Friday announced that it has completed the sale of its nutrition business to Nestlé for $11.9 billion in cash, following the conclusion of the required regulatory process in most markets.

NEW YORK — Pfizer on Friday announced that it has completed the sale of its nutrition business to Nestlé for $11.9 billion in cash, following the conclusion of the required regulatory process in most markets. In certain countries where completion will be delayed due to ongoing regulatory review, Pfizer will continue to operate the business on an interim basis.

November 30, 2012

HIV test maker OraSure Technologies has appointed a new executive to head its consumer marketing division as it prepares to launch a nationwide TV campaign on Saturday.

BETHLEHEM, Pa. — HIV test maker OraSure Technologies has appointed a new executive to head its consumer marketing division as it prepares to launch a nationwide TV campaign on Saturday.

The TV campaign will be timed to coincide with World AIDS Day on Saturday and will air on MTV, A&E, BET, E!, Bravo and Logo, as well as on the NBC reality show "The Voice" on Dec. 17.

November 29, 2012

Just how much of an impact the loss of patent protection can have on a blockbuster drug became clear earlier this year.


Just how much of an impact the loss of patent protection can have on a blockbuster drug became clear earlier this year.


November 29, 2012

The Food and Drug Administration approved a new generic drug made by Mylan for urinary disorders, the company said Thursday.

PITTSBURGH — The Food and Drug Administration approved a new generic drug made by Mylan for urinary disorders, the company said Thursday.

Mylan announced the approval and launch of tolterodine tartrate tablets in the 1-mg and 2-mg strengths. The drug is a generic version of Detrol, made by Pharmacia and Upjohn, now owned by Pfizer.

Used to treat overactive bladder, tolterodine tartrate tablets had sales of about $61.5 million during the 12-month period ended in September, according to IMS Health.

November 29, 2012

In 2011 and 2012, the steady surge of blockbuster pharmaceuticals falling off the patent cliff became a stampede. An astonishing number of big-selling drugs that had established and sustained branded drug makers’ profits for years fell victim to the expiration of their patent lives and market exclusivity, roiling the pharmaceutical marketplace and redefining the pricing model for many of the most widely prescribed classes of medicines.


In 2011 and 2012, the steady surge of blockbuster pharmaceuticals falling off the patent cliff became a stampede. An astonishing number of big-selling drugs that had established and sustained branded drug makers’ profits for years fell victim to the expiration of their patent lives and market exclusivity, roiling the pharmaceutical marketplace and redefining the pricing model for many of the most widely prescribed classes of medicines.


November 28, 2012

As New York City enjoyed the first snowfall of the winter season, industry leaders gathered for the 14th annual Industry Issues Summit to discuss the top issues and trends impacting the industry, including the importance of seizing “whitespaces.”

NEW YORK — As New York City enjoyed the first snowfall of the winter season, industry leaders gathered for the 14th annual Industry Issues Summit to discuss the top issues and trends impacting the industry, including the importance of seizing “whitespaces.”

The all-day event was held on Tuesday at the New York Athletic Club, located just across the street from Central Park.

November 27, 2012

Ranbaxy Labs has recalled more than three dozen lots of its generic version of a cholesterol-lowering statin drug due to the possible presence of foreign particles, the company said.

NEW YORK — Ranbaxy Labs has recalled more than three dozen lots of its generic version of a cholesterol-lowering statin drug due to the possible presence of foreign particles, the company said.

November 27, 2012

Reckitt Benckiser on Tuesday announced the appointment of Suzanne LoGalbo to the position of regulatory affairs director, Reckitt Benckiser North America.

PARSIPPANY, N.J. — Reckitt Benckiser on Tuesday announced the appointment of Suzanne LoGalbo to the position of regulatory affairs director, Reckitt Benckiser North America.  

LoGalbo joins RB from Pfizer Consumer Health. While at Pfizer, LoGalbo most recently held the position of global regulatory portfolio lead worldwide regulatory strategy. Prior to Pfizer, Suzanne was the head of global regulatory affairs North America for Novartis Consumer Health. She has also held regulatory leadership roles at Polaris, Solvay, Arganon and Sandoz.  

November 19, 2012

Dr. Reddy's Labs has launched a generic drug for treating pulmonary arterial hypertension, the company said.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug for treating pulmonary arterial hypertension, the company said.

Dr. Reddy's announced the launch of sildenafil tablets in the 20 mg strength in 90-count bottles. The drug is a generic version of Pfizer's Revatio.

Revatio had sales of $338.67 million during the 12-month period ended in September, according to IMS Health.

November 19, 2012

The drug-discovery division of the Cystic Fibrosis Foundation is teaming up with drug maker Pfizer to find new treatments for patients with the most common genetic mutation of the disease.

BETHESDA, Md. — The drug-discovery division of the Cystic Fibrosis Foundation is teaming up with drug maker Pfizer to find new treatments for patients with the most common genetic mutation of the disease.

November 15, 2012

The year 2012 is coming to an end, and it’s been a big year for 
generic drugs.


The year 2012 is coming to an end, and it’s been a big year for 
generic drugs.


November 13, 2012

The Food and Drug Administration has approved a generic drug made by Mylan for treating pulmonary arterial hypertension, the drug maker said Tuesday.

PITTSBURGH — The Food and Drug Administration has approved a generic drug made by Mylan for treating pulmonary arterial hypertension, the drug maker said Tuesday.

Mylan announced the FDA approval of sildenafil citrate tablets in the 20-mg strength, a generic version of Pfizer's Revatio. The drug is used to treat adults with PAH to improve exercise ability and delay clinical worsening of the condition.

Revatio had sales of about $339 million during the 12-month period ended in September, according to IMS Health.

November 12, 2012

The Food and Drug Administration has approved a generic drug for pulmonary arterial hypertension made by Watson Pharmaceuticals, the drug maker said Monday.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic drug for pulmonary arterial hypertension made by Watson Pharmaceuticals, the drug maker said Monday.

Watson said the FDA approved its sildenafil tablets in the 20 mg strength through a subsidiary. Watson said it would launch the drug "in the near future."

The drug is a generic version of Pfizer's Revatio tablets, which had sales of about $339 million during the 12-month period ended in September, according to IMS Health.

November 12, 2012

The PBM division of CVS Caremark is hoping to get patients to use lower-cost drugs for certain conditions by removing higher-cost drugs from its formulary, according to published reports.

NEW YORK — The PBM division of CVS Caremark is hoping to get patients to use lower-cost drugs for certain conditions by removing higher-cost drugs from its formulary, according to published reports.

The Wall Street Journal reported that CVS Caremark would stop covering 17 drugs starting on Jan. 1, 2013, after removing 30 this year. The drugs include Abbott's Androgel (testosterone gel) for low testosterone, and Pfizer's drug Detrol LA (tolterodine tartrate) for overactive bladder.

November 9, 2012

Earlier this week, DSN reported that members of a prescription drug program offered by Humana to Medicare beneficiaries will soon be able to obtain 10 generic hypertension drugs from Walmart for a penny.

It's certainly good news for people with high blood pressure, but it also has big implications for the pharmacy retail industry.

Earlier this week, DSN reported that members of a prescription drug program offered by Humana to Medicare beneficiaries will soon be able to obtain 10 generic hypertension drugs from Walmart for a penny.

It's certainly good news for people with high blood pressure, but it also has big implications for the pharmacy retail industry.

November 8, 2012

Business for OTC store brands is expected to boom in the coming year, Perrigo chairman and CEO Joseph Papa told analysts discussing the private-label manufacturer's first quarter results during a conference call Wednesday, even as the growth rate across the entire OTC category slows.

ALLEGAN. Mich. — Business for OTC store brands is expected to boom in the coming year, Perrigo chairman and CEO Joseph Papa told analysts discussing the private-label manufacturer's first-quarter results during a conference call Wednesday, even as the growth rate across the entire OTC category slows. "What we are seeing though, is the continued acceleration of store brand as being the reason why we're seeing the growth in our OTC category. For us to have a 9.4% growth in our OTC category, we think is a strong indication," Papa said. 

November 6, 2012

The Food and Drug Administration has approved a drug for rheumatoid arthritis ahead of the day the agency was scheduled to decide whether or not to approve it, the agency said Tuesday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug for rheumatoid arthritis ahead of the day the agency was scheduled to decide whether or not to approve it, the agency said Tuesday.

November 5, 2012

In what its president and CEO called a “significant milestone,” Watson Pharmaceuticals announced last month that the U.S. Federal Trade Commission and European Commission had approved its acquisition of Swiss generic drug maker Actavis.

In what its president and CEO called a “significant milestone,” Watson Pharmaceuticals announced last month that the U.S. Federal Trade Commission and European Commission had approved its acquisition of Swiss generic drug maker Actavis. Watson announced the $5.6 billion acquisition of Actavis in April, a deal that is expected to make Watson the third-largest generic drug maker in the world, after Teva Pharmaceutical Industries and Mylan.

October 22, 2012

Pfizer is buying the maker of an attention deficit hyperactivity disorder drug for almost $700 million, Pfizer said Monday.

NEW YORK — Pfizer is buying the maker of an attention deficit hyperactivity disorder drug for almost $700 million, Pfizer said Monday.

The drug maker announced that it would buy privately owned NextWave Pharmaceuticals, which makes the extended-release ADHD drug Quillivant XR (methylphenidate hydrochloride), which the Food and Drug Administration approved last month. The drug is expected to appear in pharmacies in January 2013.

October 22, 2012

Watson Pharmaceuticals and Actavis will have to divest rights to almost two dozen drugs as a condition for U.S. regulatory approval of their $5.6 billion merger announced earlier this year, according to regulatory documents.

NEW YORK – Watson Pharmaceuticals and Actavis will have to divest rights to almost two dozen drugs as a condition for U.S. regulatory approval of their $5.6 billion merger announced earlier this year, according to regulatory documents.